189 related articles for article (PubMed ID: 6203071)
1. Detection of malignant ovarian neoplasms: a review of the literature. III. Immunological detection and ovarian cancer-associated antigens.
Smith LH; Oi RH
Obstet Gynecol Surv; 1984 Jun; 39(6):346-60. PubMed ID: 6203071
[TBL] [Abstract][Full Text] [Related]
2. Tumor markers for ovarian cancer.
Bhattacharya M; Barlow JJ
Int Adv Surg Oncol; 1979; 2():155-76. PubMed ID: 95453
[TBL] [Abstract][Full Text] [Related]
3. Humoral immune responses to cathepsin D and glucose-regulated protein 78 in ovarian cancer patients.
Chinni SR; Falchetto R; Gercel-Taylor C; Shabanowitz J; Hunt DF; Taylor DD
Clin Cancer Res; 1997 Sep; 3(9):1557-64. PubMed ID: 9815843
[TBL] [Abstract][Full Text] [Related]
4. Characterization of humoral responses of ovarian cancer patients: antibody subclasses and antigenic components.
Taylor DD; Atay S; Metzinger DS; Gercel-Taylor C
Gynecol Oncol; 2010 Feb; 116(2):213-21. PubMed ID: 19945743
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor antibodies in ovarian cancer.
Luborsky JL; Barua A; Shatavi SV; Kebede T; Abramowicz J; Rotmensch J
Am J Reprod Immunol; 2005 Aug; 54(2):55-62. PubMed ID: 16105096
[TBL] [Abstract][Full Text] [Related]
6. Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer.
Garg M; Chaurasiya D; Rana R; Jagadish N; Kanojia D; Dudha N; Kamran N; Salhan S; Bhatnagar A; Suri S; Gupta A; Suri A
Clin Cancer Res; 2007 Mar; 13(5):1421-8. PubMed ID: 17332284
[TBL] [Abstract][Full Text] [Related]
7. Tumor-reactive immunoglobulins in ovarian cancer: diagnostic and therapeutic significance? (review).
Taylor DD; Gercel-Taylor C
Oncol Rep; 1998; 5(6):1519-24. PubMed ID: 9769398
[TBL] [Abstract][Full Text] [Related]
8. Autologous antibodies eluted from membrane fragments in human ovarian epithelial neoplastic effusions. II. Tissue specificity and reactivity.
Kutteh WH; Doellgast GJ
J Natl Cancer Inst; 1986 May; 76(5):797-804. PubMed ID: 3517453
[TBL] [Abstract][Full Text] [Related]
9. [Immunodiagnostic studies in ovarian cancer using the leukocyte adherence inhibition test (LAI test). 1. Detection of cellular sensitization of peripheral blood lymphocytes using the LAI test].
Ludwig HJ; Storch H
Zentralbl Gynakol; 1986; 108(10):593-606. PubMed ID: 3526755
[TBL] [Abstract][Full Text] [Related]
10. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.
Goodell V; Salazar LG; Urban N; Drescher CW; Gray H; Swensen RE; McIntosh MW; Disis ML
J Clin Oncol; 2006 Feb; 24(5):762-8. PubMed ID: 16391298
[TBL] [Abstract][Full Text] [Related]
11. T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer.
Knutson KL; Krco CJ; Erskine CL; Goodman K; Kelemen LE; Wettstein PJ; Low PS; Hartmann LC; Kalli KR
J Clin Oncol; 2006 Sep; 24(26):4254-61. PubMed ID: 16908932
[TBL] [Abstract][Full Text] [Related]
12. Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers.
Peoples GE; Anderson BW; Lee TV; Murray JL; Kudelka AP; Wharton JT; Ioannides CG
Clin Cancer Res; 1999 Dec; 5(12):4214-23. PubMed ID: 10632363
[TBL] [Abstract][Full Text] [Related]
13. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
[TBL] [Abstract][Full Text] [Related]
14. Identification of a human cancer-associated antigen defined with monoclonal antibody.
Bhattacharya M; Chatterjee SK; Barlow JJ
Cancer Res; 1984 Oct; 44(10):4528-34. PubMed ID: 6380708
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer.
Reinartz S; Hombach A; Köhler S; Schlebusch H; Wallwiener D; Abken H; Wagner U
Cancer Res; 2003 Jun; 63(12):3234-40. PubMed ID: 12810653
[TBL] [Abstract][Full Text] [Related]
16. [Studies on immunospecificity of skin test using tumor extract in gynecological malignancy (author's transl)].
Yuzawa H
Nihon Sanka Fujinka Gakkai Zasshi; 1980 May; 32(5):611-8. PubMed ID: 6165790
[TBL] [Abstract][Full Text] [Related]
17. Humoral p53 antibody response is a prognostic parameter in ovarian cancer.
Mayerhofer K; Tempfer C; Kucera E; Hefler L; Zeisler H; Kainz C; Zeillinger R; Sliutz G
Anticancer Res; 1999; 19(1B):875-8. PubMed ID: 10216509
[TBL] [Abstract][Full Text] [Related]
18. Cell-mediated immunity and blocking factor in ovarian carcinoma.
Mitchell MS; Kohorn EI
Obstet Gynecol; 1976 Nov; 48(5):590-7. PubMed ID: 980285
[TBL] [Abstract][Full Text] [Related]
19. A monoclonal antibody radioimmunoassay for an antigenic determinant CA125 in ovarian cancer patients.
Lian LJ; Hu XF; Liu WS; Wu AJ
Chin Med J (Engl); 1986 Sep; 99(9):721-6. PubMed ID: 2433106
[No Abstract] [Full Text] [Related]
20. [Circulating IgG-containing immune complexes in malignant growth].
Kostrzhevskaia EG
Eksp Onkol; 1986; 8(3):10-7. PubMed ID: 2424714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
